文献速递腹部技术与安全CT

光子计数探测器CT与双能量CT在标准参考图像条件下对胰腺癌的定量与定性评估

Quantitative and qualitative evaluation of pancreatic cancer on photon-counting detector CT and dual-energy CT using standard reference images.
PubMed 文献 · Abdom Radiol (NY) · 2026-03-03

回顾性单中心研究纳入124例病理证实的胰腺癌患者(PCD-CT组62例、DE-CT组62例),在等效120 kVp参考条件下比较两种CT对肿瘤的显示能力。PCD-CT在平衡期肿瘤可见度评分高于DE-CT(3.065 vs 2.548,p<0.001),校正后仍显著(β=+0.305,p=0.032);两组定量参数(TPR、CNR)及胰腺期可见度无显著差异。

要点

  • 平衡期PCD-CT肿瘤可见度评分高于DE-CT(3.065 vs 2.548,p<0.001),校正后仍显著(β=+0.305,p=0.032)。
  • 胰腺期可见度评分两组无显著差异(4.250 vs 4.065,p=0.136)。

核心结论

  • 在等效120 kVp条件下,PCD-CT与DE-CT对胰腺癌的定量表现相当,而PCD-CT在平衡期提供更优的主观肿瘤可见度,提示视觉可检测性改善且不损失定量图像质量。

研究设计与样本

  • 回顾性单中心研究,纳入2023年1月至2024年10月间接受初次动态增强上腹部CT且病理证实胰腺癌的124例患者(PCD-CT组n=62,DE-CT组n=62)。

关键影像表现/征象

  • PCD-CT参考图像为70 keV虚拟单能图像,DE-CT参考图像为80/Sn150 kVp线性融合图像。
  • 平衡期肿瘤可见度评分PCD-CT组3.065 vs DE-CT组2.548(p<0.001),校正年龄、BMI、肿瘤大小及位置后仍显著(β=+0.305;p=0.032)。
  • 胰腺期可见度评分PCD-CT组4.250 vs DE-CT组4.065(p=0.136),两组无显著差异。
  • 肿瘤≤20 mm亚组(胰腺期)结果与主分析一致。

诊断标准与关键数值

  • 胰腺期TPR:PCD-CT组0.495 vs DE-CT组0.537(p=0.088),无显著差异。
  • 胰腺期CNR:PCD-CT组13.789 vs DE-CT组12.231(p=0.246),无显著差异。
  • 平衡期TPR:PCD-CT组1.027 vs DE-CT组1.017(p=0.868),无显著差异。
  • 平衡期CNR:PCD-CT组0.901 vs DE-CT组0.110(p=0.597),无显著差异。
  • 两名放射科医师独立采用五分法评估肿瘤可见度,取平均可见度评分进行分析。

临床应用与阅片要点

  • 在等效120 kVp条件下,PCD-CT平衡期图像可能提供更好的胰腺癌主观可见度,阅片时可关注平衡期肿瘤与胰腺实质的对比显示。
  • 两组定量参数(TPR、CNR)无显著差异,定量评估时两种设备可参照各自参考图像条件进行解读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare the depiction performance of photon-counting detector CT (PCD-CT) and dual-energy CT (DE-CT) quantitatively and qualitatively for pancreatic cancer under reference conditions equivalent to 120 kVp, used in clinical practice.

METHOD: For this retrospective single-center study, 124 patients with pathologically proven pancreatic cancer who had undergone initial dynamic contrast-enhanced upper abdominal CT between January 2023 and October 2024 were included (PCD-CT: n = 62; DE-CT: n = 62). Reference images were 70 keV virtual monoenergetic images for PCD-CT and 80/Sn150 kVp linearly blended images for DE-CT. The tumor-to-pancreas ratio (TPR) and contrast-to-noise ratio (CNR) were calculated in the pancreatic and equilibrium phases. After two radiologists rated tumor visibility independently using a five-point scale, the mean visibility score was analyzed. Group differences were assessed using Welch's t test and linear regression adjusted for age, body mass index (BMI), tumor size, and tumor location. A predefined subgroup analysis was conducted for tumors ≤ 20 mm (pancreatic phase).

RESULT: In the equilibrium phase, the visibility score was higher with PCD-CT than with DE-CT (3.065 vs. 2.548; p < 0.001) and remained significant after adjustment (β = +0.305; p = 0.032). TPR and CNR were similar in both phases (pancreatic: TPR 0.495 vs. 0.537, p = 0.088; CNR 13.789 vs. 12.231, p = 0.246; equilibrium: TPR 1.027 vs. 1.017, p = 0.868; CNR 0.901 vs. 0.110, p = 0.597), as was pancreatic-phase visibility (4.250 vs. 4.065; p = 0.136). Results for tumors ≤ 20 mm were consistent with the main analysis.

CONCLUSION: Under 120 kVp-equivalent conditions, PCD-CT and DE-CT showed comparable quantitative performance for pancreatic cancer, whereas PCD-CT provided superior subjective tumor visibility in the equilibrium phase, suggesting improved visual detectability without loss of quantitative image quality.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Niiyama T, Naruto N, Nishikawa K, et al. Quantitative and qualitative evaluation of pancreatic cancer on photon-counting detector CT and dual-energy CT using standard reference images. Abdom Radiol (NY). 2026. PMID: 41774137. doi:10.1007/s00261-026-05444-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。